Adma Biologics (ADMA) Depreciation & Amortization (CF) (2011 - 2025)

Adma Biologics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• Quarterly Depreciation & Amortization (CF) rose 5.25% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (up 0.63% YoY) and the FY2025 annual result came in at $8.1 million, up 0.63% from the prior year.
• Depreciation & Amortization (CF) was $2.0 million for Q4 2025 at Adma Biologics, up from $2.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q1 2024 and bottomed at $1.2 million in Q1 2021.
• A 5-year average of $1.9 million and a median of $2.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 55.88% — and 2024, when it fell 7.82%.
• Adma Biologics' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then grew by 27.55% to $1.9 million in 2022, then rose by 8.91% to $2.1 million in 2023, then declined by 7.82% to $1.9 million in 2024, then gained by 5.25% to $2.0 million in 2025.
• Business Quant data shows ADMA's Depreciation & Amortization (CF) at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.1 million in Q2 2025.